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The relationship between gene dosage, enzyme activity, and level of immunologically cross-reacting material 
(CRM) was examined in mammalian tyrosinase (EC 1.14.18.1) by rocket immunoelectrophoresis. Skin ex- 
tracts from mice heterozygous (C/c) and homozygous (c/c) for the albino locus contain 46% and 0% of 
CRM, respectively, as compared with wild-type (C/C) animals. Enzyme activity and CRM level were direct- 
ly proportional in these genotypes, uggesting that the albino locus controls the quantity of tyrosinase pro- 
duced in meianocytes. 
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1. INTRODUCTION 
Mammalian tyrosinase, a copper-containing 
glycoprotein, is a key enzyme in melanin synthesis. 
In the mouse, the albino (c-) locus at chromosome 
7 has been assumed to be the structural gene for 
tyrosinase, since mice homozygous for albino (c) 
alleles at this locus entirely lack melanin pigment. 
Some reports have shown that there is no detec- 
table tyrosinase activity in skin extracts of albino 
mice [1,2]. In contrast, other reports have shown 
minimal but significant activity in skins [3] and 
eyes [4] of albino mice, and in the skins of albino 
hamsters [3]. Moreover, the presence of tyrosinase 
inhibitors has been suggested in albino axolotls [5], 
human albinos [6], and mice carrying a mutation 
at the c-locus [7]. Therefore, the real reason for the 
absence of tyrosinase activity in albino mutants re- 
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mains unclear. Here, the level of tyrosinase CRM 
was measured directly by rocket immunoelectro- 
phoresis (RIE), to determine whether the albino 
mutants produce inactive tyrosinase. 
2. MATERIALS AND METHODS 
2.1. Preparation of antiserum 
Melanosomal tyrosinase used as an antigen was 
purified from Harding-Passey (HP) mouse 
melanoma as described [S]. Briefly, melanosomal 
tyrosinase was solubilized from large granule frac- 
tion [9] with trypsin and DOC, and subjected to 
chromatography on Ultrogel AcA 34. Eluate was 
further subjected to DE32 in batch, chromatog- 
raphy on Ultrogel AcA 44, DEAE-Sephadex A-25 
at pH 7.4 and pH 6.0. At the final purification 
step, tyrosinase was separated by PAGE followed 
by electroelution [lo]. Purified tyrosinase was also 
subjected to analytical SDS-PAGE according to 
Laemmli [l 11. Antiserum against the purified 
tyrosinase was raised in a rabbit. Specificity of the 
antiserum was determined by Ouchterlony double 
immunodiffusion in agarose (medium EEO, 
Sigma) containing 1% TRX [ 121. 
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2.2. Immunoelectrophoresis 
Immunoelectrophoresis was carried out as in 
[13] except that 1% TRX was added to agarose 
gels. For RIE, 5 ~1 samples were placed in 2-mm 
wells in agarose plate (12 x 10 cm), and run at 
20 V for 18 h. To detect tyrosinase activity, gel 
plates were incubated in 0.1% Dopa, 0.1 M 
sodium phosphate buffer (pH 7.2) for 1 h at 
37°C. Gels were also stained with CB to visualize 
immunoprecipitin lines. 
2.3. Preparation of tissue extracts 
Albino (DDY) and black (C57BL/6) mice were 
obtained from Funabashi Farm Co., Japan. Mice 
heterozygous (C/c) for the c-locus were the off- 
spring of a cross between DDY (c/c) and C57BL/6 
(C/C). Dorsal skins from 5-day-old newborn mice 
were excised, washed 3 times with phosphate- 
buffered saline to remove blood contaminant, and 
homogenized with 20 vols of 0.5% DOC, 50 mM 
Tris-HCl (pH 7.4). After being left for 1 h at 4°C 
the homogenate was centrifuged at 100000 x g 
(max) for 90 min. The resulting supernatant was 
mixed with l/9 vol. of 10% trypsin (Difco 1:250) 
and incubated for 1 h at 37°C. Tryptic digestion 
was stopped by adding 4 mM PMSF. The superna- 
tant was then subjected to ammonium sulfate frac- 
tionation. The precipitate at 60% saturation was 
recovered, dissolved with a minimum amount of 
10 mM Tris-HCl buffer, pH 7.4, dialysed against 
distilled water for 18 h at 4”C, and lyophilized to 
concentrate the sample. The activity of tyrosinase 
was measured calorimetrically at 475 nm with 
Dopa as substrate [14]. Protein content was 
measured according to Lowry et al. [ 151. 
3. RESULTS AND DISCUSSION 
The M, of the purified tyrosinase was estimated 
to be about 68000 by SDS-PAGE (fig.1). This 
value is similar to those reported for melanosomal 
tyrosinase [16-181. 
Monospecificity of the antiserum was confirmed 
by double immunodiffusion. A single precipitin 
line was formed against he purified tyrosinase and 
crude homogenate of HP melanoma (fig.2). Dopa 
oxidase activity was detected on the precipitin line 
(not shown). 
The purified tyrosinase used as an antigen was 
supposed to be the particulate form (T3) according 
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Fig. 1. SDS-PAGE pattern of purified tyrosinase. Lane 
1, marker proteins: phosphorylase a (92 kDa), bovine 
serum albumin (68 kDa), and ovalbumin (43 kDa). 
Lanes 2 and 3, purified tyrosinase (5 pg). Gels were 
stained with CB (lane 2), or incubated with Dopa to 
detect Dopa-oxidase activity (lane 3). 
to Nishioka [16]. However, the antiserum also 
cross-reacted with soluble tyrosinase which cor- 
responds to Tl and T2 forms (fig.3). The precipitin 
lines against soluble and particulate tyrosinase 
fused completely, showing the presence of iden- 
tical determinants in these isoforms as reported in 
]191. 
Since most of the tyrosinase exists in the par- 
ticulate form, solubilization of tyrosinase from the 
Fig.%. Ouchterlony double immunodiffusion analysis. 
Well 1, 5 ~1 anti-tyrosinase antiserum; well 2, serum 
from DDY mouse; well 3, liver cell sap of DDY mouse; 
well 4, homogenate of HP mouse melanoma; well 5, 
purified tyrosinase. Gel was stained with CB. 
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solubilized proteins often interferes with the 
specific binding of an antibody. In our method, 
the specificity of the immunoprecipitation of 
tyrosinase was further confirmed by staining preci- 
pitin lines with Dopa. Usually, gels containing a 
I:200 dilution of the antiserum were used. The 
area under the rocket is proportional to the 
amount of antigen in the range 0.2-3.5 gg (fig.4). 
By using different concentrations of antiserum, the 
linearity of the quantitation of antigen was well 
preserved up to 2Opg antigen concentration. 
Previously, Coleman [l] determined the amount 
of tyrosine incorporation into melanin pigment in 
skins from various c-locus genotypes, and found 
that the value obtained in heterozygotes (C/c) was 
intermediate between those in wild (C/C) and 
albino (c/c) homozygotes. Recently, Murray et al. 
[2] reported the absence of tyrosinase and Dopa- 
oxidase activities in extracts of albino skin. 
However, these workers did not measure the 
amount of tyrosinase in mice of different geno- 
types. In this study, we found that the tyrosinase 
activity in skin extract was directly proportional to 
the amount of tyrosinase determined by RIE, in 
both C/C and C/c genotypes (table 1). Both the 
Fig.3. Immunological cross-reaction of anti-tyrosinase 
antiserum with soluble and particulate forms of 
tyrosinase. Tyrosinases were solubilized from HP mouse 
melanoma and subjected to crossed immunoelectro- 
phoresis (A) or immunoelectrophoresis (B), without fur- 
ther purification. Precipitin lines against particulate (p) 
and soluble (s) tyrosinase fused completely on crossed 
immunoelectrophoresis (A). It was also confirmed by 
immunoelectrophoresis (B). Lane 1, solubilized fraction 
of HP melanoma, which contains both soluble and par- 
ticulate tyrosinases. Lane 2, particulate tyrosinase 
purified from large granule fraction. Gels were stained 
with Dopa. 
organelles in a prerequisite for the accurate quan- 
titation of the total amount of the enzyme in 
tissues. Here, approx. 70% of the tyrosinase activi- 
ty was recovered in the solubilized samples at the 
final preparation step as compared with the crude 
homogenates. For immunodiffusion and immuno- 
electrophoresis, TRX was added to agarose gels to 
prevent non-specific aggregation of proteins. 
Although there are several reports on the immu- 
nological identification of tyrosinase [ 12,19-211, a
quantitative study on the amount of the enzyme in 
skin has not been reported. Halaban et al. [22] 
determined the abundance of tyrosinase in 
cultured melanocytes by using immunoprecipita- 
tion of 35S-labeled proteins 1221. Their method, 
however, is rather difficult to apply for measure- 
ment of the amount of tyrosinase in skin. Alter- 
native techniques, such as ELISA and radioim- 
munoassay, may offer higher sensitivity than our 
method, but may be less reliable for the quantita- 
tion since non-specific aggregation of detergent- 
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Fig.4. Standard curve for quantnation of the amount of 
tyrosinase CRM. (A) Purified tyrosinase was subjected 
to RIE as standard. Area under the rocket was measured 
and plotted against the dose of standard tyrosinase. (B) 
Gel plate for RIE after staining it with Dopa. Each well 
contained 0.22 pg (1). 0.44 ,ug (2), 0.88 pg (3), 1.76 pg 
(4), and 3.52,~g (5) of purified tyrosinase. 
281 
Volume 183, number 2 FEBS LETTERS 
Table 1 
The relationship between tyrosinase activity and its content estimated from RIE in skin 
extracts 
Genotype Activity= Content Specific activity 
(units x 10F3/mg kg tyrosinase/mg (units/mg 
total protein) total protein) tyrosinase) 
C/C 1.84 f 0.87 0.72 +_ 0.13 10.9 
c/c 3.48 +_ 1.23 0.33 + 0.10 10.5 
c/c 0.09 f 0.02 ND _ 
a Specific activity of tyrosinase was calculated as a/b. ND, no precipitin line was detected. 
Each value is the mean + SD of 3 experiments 
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total enzyme activity and the amount of tyrosinase 
in C/c skin were almost half of those in C/C skin, 
although the specific activity of tyrosinase did not 
differ between the two. Precipitin line was not 
formed against the extract of albino (c/c) skin, 
showing the absence of tyrosinase CRM in detec- 
table amounts in albino mice. This result clearly 
suggests that the dose effect of the albino gene 
plays a definite role in tyrosinase production. 
It must be mentioned here that the P and ch 
genes, the other mutations at the c-locus, have 
been suggested to influence the structure of 
tyrosinase [ 1,7,23]. The polyclonal antibody used 
in our study is supposed to recognize various im- 
munological determinants on tyrosinase. There- 
fore, it is difficult to distinguish minor changes in 
the immunogenicity of tyrosinase such as expected 
in these mutations. The use of monoclonal anti- 
bodies in our immunological method will provide 
further information on the relationship between 
gene doses and its expression as well as the struc- 
tural specificity of the albino tyrosinase. 
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